AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Restasis [legacy through FY24] by Year
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%) (%)
AbbVie Restasis [legacy through FY24]: -55.2% in FY2024, down 16.7 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| Restasis | 172 | 52 | 224 | (55.2) | (3.0) | (48.7) | 2.1 | (48.1)”
Source: Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | -55.2% | -16.7 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | -38.5% | +11.1 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | -49.6% | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie Restasis [legacy through FY24] (%), annual FY2022–FY2024 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/restasis-us-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.